Research

Dr. Bartolini has a track record of funded highly competitive research grants as Principal Investigator (PI) and Co-Principal Investigator (Co-PI) in the United States.

During his career as a clinician-scientist, Dr. Bartolini has been involved in several clinical and translational research projects regarding epilepsy, ranging from studying viral and inflammatory mechanisms involved in the pathophysiology of epilepsy to imaging characteristics of drug-resistant pediatric epilepsy and to inflammatory mechanisms involved in super-refractory status epilepticus in children. More recently, Dr. Bartolini’s research focus has been to analyze neurophysiological features of rare genetic epilepsies, and decoding gene expression in surgically resected brain specimens from children affected by Rasmussen Encephalitis, a rare and devastating form of drug-resistant epilepsy.

Dr. Bartolini’s overarching research goal is to elucidate disease mechanisms involved in the development of drug-resistant epilepsy in children, with the aim of translating these discoveries into clinical practice as potential targets for novel therapeutic approaches and ultimately to improve the quality of life of children affected by this severe condition and their families.

Funded Research Grants:

  • Children’s Miracle Network Annual Scholar Award
    “Transcriptomics Analysis of Brain Specimens from Children with Rasmussen
    Encephalitis”
    Role: PI
    $25,000
  • Advance Clinical and Translational Research / Brown University IDeA grant (NIH U54GM115677)
    “Epilepsy and Neurocognitive Function in Patients with Neurogenetic Disorders” Role: Co-PI
    $104,580
  • American Epilepsy Society / Epilepsy Foundation of America
    Research and Training Fellowship for Clinicians
    “Research study on viral and inflammatory causes of epilepsy”. Role: PI
    $50,000

Other Research Activity:

  • Hasbro Children’s Hospital Site Principal Investigator / Representative; Member of the Pediatric Epilepsy Surgery and Infantile Spasms SIG
    Pediatric Epilepsy Research Consortium (PERC)
    May 2021 – June 2023
  • Co-Investigator, “Electroencephalographic, genetic characteristics and treatment response in pediatric epilepsy associated with autism spectrum disorders”
    March 2021 – June 2023
  • Co-Investigator, “Natural history of ASH1L associated autism and neural cellular studies”
    December 2020 – June 2023
  • Principal Investigator, “Analysis of anti-seizure medication side-effects leading to discontinuation of therapy in pediatric epilepsy”.

November 2020 – July 2022